Compare BridgeBio Pharma Inc (BBIO) vs Chewy Inc (CHWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Chewy Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Chewy Inc trades at $22.61 (market cap $9.25B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Chewy Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | CHWY | |
|---|---|---|
Market Cap | $16.61B | $9.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $42.33 |
52-Week Low | $47.29 | $17.51 |
Enterprise Value | $18.16B | $9.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Chewy (CHWY) trades at $23.53, up 0.43% with a bullish technical signal supported by moving averages. The company shows strong revenue growth from $8.9B in 2022 to $11.86B in 2025, with net income turning positive at $393M. Recent earnings beat expectations in Q1 2026 with EPS of $0.43 versus $0.24 expected. Analyst consensus remains strongly bullish with 81.58% buy ratings and a $33.82 price target, representing 44% upside potential from current levels.
Chewy's outlook appears favorable with expanding veterinary services and Autoship subscription model driving recurring revenue. Key risks include competitive pressure from Amazon and Walmart, insider selling activity, and margin compression as net income margin is projected to decline to 1.98% in 2026. The stock offers growth potential but requires monitoring of execution against aggressive expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →
